Willow bark of the willow tree have been mentioned in ancient texts from Assyria, Sumer and Egypt as a remedy for aches and fever, and in Ancient Greece the physician Hippocrates wrote about its medicinal properties in the fifth century BC. Native Americans across the Americas relied on it as a staple of their medical treatments. It provides temporary pain relief. Salicin is metabolized into salicylic acid in the human body, and is a precursor of aspirin. In 1763, its medicinal properties were observed by the Reverend Edward Stone in England. He notified the Royal Society, which published his findings. The
Nonsteroidal anti-inflammatory drug inflammation and also used willow bark to mitigate them. On 25 April 1763, Edward Stone wrote to the Royal Society describing his observations on the use of willow bark-based medicines in febrile patients. The active ingredient of willow bark, a glycoside called salicin, was first isolated by Johann Andreas Buchner in 1827. By 1829, French chemist Henri Leroux had improved the extraction process to obtain about 30g of purified salicin from 1.5 kg of bark. By hydrolysis, salicin releases glucose and salicylic alcohol which can be converted into salicylic acid, both in vivo and through chemical methods. The acid is